nystatin-a1 and Lymphoma

Topics: Adult; Amphotericin B; Candidiasis; Female; Gastrointestinal Diseases; Histoplasmosis; Humans; Infant; Leukemia; Lymphoma; Male; Mucormycosis; Mycoses; Nystatin

Topics: Adolescent; Adult; Clinical Trials as Topic; Humans; Ketoconazole; Leukemia; Lymphoma; Mycoses; Nystatin; Oropharynx; Species Specificity; Yeasts

Fifty-eight patients with malignant lymphoma were randomly allocated to receive three courses of chemotherapy to induce remission with CHOP-Bleo on the protected environment-prophylactic antibiotic (PEPA) program (30 patients) or as controls (28 patients). The complete remission rate for all patients was 74 per cent, for patients with diffuse histiocytic lymphoma 78 per cent and for patients with nodular poorly differentiated lymphocytic lymphoma 65 per cent. There were no significant differences in response rates and duration of responses between those on the PEPA program and control patients. The frequency of infection was significantly lower among the patients on the PEPA program, and dosage escalation of the chemotherapeutic agents was accomplished more often among these patients. Dosage escalation did not increase the complete remission rate, but it did reduce the relapse rate and signficantly reduced the fatality rate. The duration of remission and survival was significantly longer for those patients who received dosage escalation.

Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Gentamicins; Humans; Immunosuppression Therapy; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Middle Aged; Nystatin; Patient Isolation; Prednisone; Vancomycin; Vincristine

Gastrointestinal Candida infection is more prevalent than previously recognized. It is most often seen in patients with underlying impairment of the immune system but may also occur in apparently normal individuals. Esophageal involvement is most common, presenting with odynophagia, dysphagia, or bleeding. Gastric Candida infection may cause diffuse mucosal involvement or focal invasion of benign gastric ulcers. Intestinal candidiasis is uncommon and poorly characterized. The diagnosis is usually established by visualizing the characteristic yeast or mycelial forms in endoscopic brushings and biopsies. Oral nystatin is effective therapy in many patients, but other antifungal agents may be needed in extensive or persistent disease, especially in immunocompromised patients.

Topics: Candidiasis; Deglutition Disorders; Diagnosis, Differential; Esophageal Diseases; Flucytosine; Humans; Imidazoles; Intestinal Diseases; Leukemia; Lymphoma; Lymphoma, Non-Hodgkin; Nystatin; Polyenes; Stomach Diseases

Thirty-three patients with acute leukemia or lymphoma received an ongoing topical treatment with an oral suspension of nystatin during prolonged periods of intensive chemotherapy and severe granulocytopenia. The preparation proved ineffective in eliminating colonized Candida species from the oropharynx in ten of eleven patients at the time of admission and was of questionable value in preventing later colonization in others. The difficulties surrounding the identification of systemic candidiasis, its significance in the immunosuppressed patient, and the role of topical antifungal prophylaxis are discussed.

Topics: Adolescent; Adult; Aged; Candida; Candidiasis, Oral; Female; Humans; Immunosuppression Therapy; Leukemia; Lymphoma; Male; Middle Aged; Nystatin; Oropharynx; Pharyngeal Diseases

Topics: Candidiasis; Humans; Leukemia; Lymphoma; Nystatin

Topics: Candidiasis; Candidiasis, Oral; Humans; Leukemia; Lymphoma; Nystatin

Topics: Candidiasis; Humans; Leukemia; Lymphoma; Nystatin